Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...

Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable ...

Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate ...

Bangalore: AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from ...

Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or ...

AstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and ...

The monoclonal antibody cetuximab (Erbitux) was more effective than a newer drug, the immune checkpoint inhibitor medicine durvalumab (Imfinzi), in fighting head-and-neck tumors, the trial found.

AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from the CDSCO, ...

This approval establishes the use of Olaparib in combination with Durvalumab as a maintenance treatment for adult patients ...

AstraZeneca Pharma India has gained approval from India's drug regulator to import cancer treatment drug Lynparza for sale. The tablets are for use in combination therapy for patients with specific ...

Discover the trials that have shown why Predictive biomarkers are expected to play a pivotal role in further enhancing ...

AstraZeneca Pharma India has received approval from the CDSCO for Olaparib film-coated tablets, set to launch in India for ...